Sponsor:
Caris Science, Inc.
Code:
NCT07680868
Conditions
Acute Myeloid Leukemia (AML)
Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
Myelodysplatic Syndromes
Myeloproliferative Neoplasm
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Caris Chromoseq
Brief summary:
Conditions
Acute Myeloid Leukemia (AML)
Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases
Myelodysplatic Syndromes
Myeloproliferative Neoplasm
Study ID
NCT07680868
Start date
Jul, 2026
Status verified date
Jun, 2026
Completion date
Jul, 2029
Anticipated
Primary completion date
Jul, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
300 participants
Anticipated
Arms
AML, MDS and/or MPN
Interventions
Caris Chromoseq
Primary outcome measure
Central contacts
Locations
Caris Life Sciences
Recruiting
Phoenix, Arizona, United States, 85040
Contacts
Sponsor
Caris Science, Inc.
Last update posted
Jul 2, 2026
Last verified
Jun, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Caris Science, Inc. on 2026-07-02.